Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study

Consolidation treatment of advanced ovarian carcinoma, especially the place of intraperitoneal chemotherapy, remains a controversial subject. From January 1988 to July 1995, 39 patients, median age 54 years, received intraperitoneal chemotherapy as consolidation treatment after second-look surgery....

Full description

Saved in:
Bibliographic Details
Published inBulletin du cancer Vol. 86; no. 7-8; p. 673
Main Authors Gladieff, L, Chatelut, E, Gaspard, M H, Skaf, R, de Forni, M, Mihura, J, Canal, P, Bugat, R
Format Journal Article
LanguageFrench
Published France 01.07.1999
Subjects
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adenocarcinoma - surgery
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Cisplatin - administration & dosage
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Doxorubicin - administration & dosage
Female
Humans
Injections, Intraperitoneal
Middle Aged
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Pilot Projects
Survival Analysis
Online AccessGet more information

Cover

More Information
Summary:Consolidation treatment of advanced ovarian carcinoma, especially the place of intraperitoneal chemotherapy, remains a controversial subject. From January 1988 to July 1995, 39 patients, median age 54 years, received intraperitoneal chemotherapy as consolidation treatment after second-look surgery. At the time of intraperitoneal chemotherapy, 30 patients had no residual disease. Intraperitoneal drug administration used a Tenckoff catheter or a lumbar needle. Treatment combined 5 fluorouracil 1 g/m2 and cisplatin 200 mg/m2, associated with a systemic sodium thiosulfate rescue as nephroprotector. A pharmacological analysis was done for 9 patients: the exposure of peritoneal cavity to cisplatin exceeded that of the plasma by 11 fold. Hematologic and nephrologic toxicity were acceptable. The median follow-up is 43 months. The disease free survival is 36,6 months, but 48,5 months if no residual disease at the time of intraperitoneal chemotherapy. Consolidation treatment by intense intraperitoneal chemotherapy is a feasible approach and might be beneficial in chemosensitive patients devoid of macroscopic remnants, but must be compared with others approaches.
ISSN:0007-4551